ILMN Stock Analysis: Illumina | NASDAQ

Sequencing Instruments, Array Instruments, Sequencing Kits, Reagents

Total Rating 71

Safety 77

Buy Signal 0.57

Diagnostics & Research
Industry Rotation: -10.9

Market Cap: 28.4B
Avg Turnover: 349M

Risk 3d forecast

Volatility40.9%

VaR 5^th Pctl6.95%

VaR vs Median2.98%

Reward TTM

Sharpe Ratio1.51

Rel. Str. IBD92.1

Rel. Str. Peer Group73.2

Character TTM

Beta1.077

Beta Downside0.992

Hurst Exponent0.448

Drawdowns 3y

Max DD57.10%

CAGR/Max DD0.10

CAGR/Mean DD0.22

EPS (Earnings per Share)

EPS CAGR: 125.12%
EPS Trend: 95.5%

Last SUE: 0.32
Qual. Beats: 0

Revenue

Rev. CAGR: -0.91%
Rev. Trend: -45.6%

Last SUE: 1.93
Qual. Beats: 4

Warnings

Below Avwap Earnings

Tailwinds

Rs Leader

Idiosyncratic Leader

Seasonality 11.6 years of data

Jan +3.9% 21

Feb -2.1% 31

Mar +2.1% 18

Apr -1.5% 31

May +0.7% 17

Jun +0.9% 20

Jul +8.0% 46

Aug -0.6% 2

Sep -0.9% 14

Oct -1.3% 11

Nov +3.0% 26

Dec -0.2% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: ILMN Illumina

Illumina, Inc. is a global provider of sequencing- and array-based solutions for genetic and genomic analysis, operating across the Americas, Europe, Greater China, Asia Pacific, the Middle East, and Africa. The company sits within the Health Care sector, specifically the Life Sciences Tools & Services sub-industry, which supplies instruments, reagents, and analytical services used in biological research and clinical applications.

Its product offering centers on sequencing and array-based instruments paired with consumables such as reagents, flow cells, and library preparation tools. It also sells whole-genome sequencing kits and targeted resequencing kits designed for exomes, specific genes, and RNA or other genomic regions. Complementary services include whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support.

Illumina serves a broad customer base that includes genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Products are sold both directly and through life-science distributors.

The company maintains several external partnerships, including a collaboration with Labcorp Holdings to develop oncology treatments using sequencing solutions, a strategic collaboration with Integrated DNA Technologies to build an integrated end-to-end workflow for somatic oncology research, and a data partnership with the Center for Data-Driven Discovery in Biomedicine focused on pediatric cancer and rare disease research.

Illumina was incorporated in 1998 and is headquartered in San Diego, California.

Headlines to Watch Out For

China sequencing revenue declines on biosecure act restrictions
NovaSeq X placements expand installed base and consumables revenue
Element and MGI competition pressures sequencing instrument pricing margins
Grail divestiture proceeds deployed to share repurchases and debt reduction

Piotroski VR-10 (Strict) 6.5

Net Income: 825.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.14 > 0.02 and ΔFCF/TA -2.82 > 1.0
NWC/Revenue: 27.95% < 20% (prev 27.56%; Δ 0.40% < -1%)
CFO/TA 0.16 > 3% & CFO 1.09b > Net Income 825.0m
Net Debt (1.91b) to EBITDA (1.36b): 1.40 < 3
Current Ratio: 1.80 > 1.5 & < 3
Outstanding Shares: last quarter (153.0m) vs 12m ago -2.55% < -2%
Gross Margin: 66.79% > 18% (prev 67.14%; Δ -0.35% > 0.5%)
Asset Turnover: 70.55% > 50% (prev 70.35%; Δ 0.20% > 0%)
Interest Coverage Ratio: 10.79 > 6 (EBIT TTM 1.09b / Interest Expense TTM 101.0m)

Altman Z'' 3.15

A: 0.19 (Total Current Assets 2.83b - Total Current Liabilities 1.58b) / Total Assets 6.65b
B: -0.01 (Retained Earnings -51.0m / Total Assets 6.65b)
C: 0.17 (EBIT TTM 1.09b / Avg Total Assets 6.37b)
D: 0.74 (Book Value of Equity 2.84b / Total Liabilities 3.81b)
Altman-Z'' = 3.15 = A

Beneish M -2.93

DSRI: 1.02 (Receivables 764.0m/716.0m, Revenue 4.49b/4.28b)
GMI: 1.01 (GM 67.14% / 66.79%)
AQI: 1.09 (AQ_t 0.41 / AQ_t-1 0.38)
SGI: 1.05 (Revenue 4.49b / 4.28b)
TATA: -0.04 (NI 825.0m - CFO 1.09b) / TA 6.65b)
Beneish M = -2.93 (Cap -4..+1) = A

What is the price of ILMN shares?

As of August 17, 2026, the stock is trading at USD 190.89 with a total of 993,041 shares traded. Over the past week, the price has changed by +1.56%, over one month by -0.16%, over three months by +33.27% and over the past year by +90.72%.

Current recommended Stop Loss: 170.20 (which is 10.8% or 2.7 ATR below the current price).

Is ILMN a buy, sell or hold?

Illumina has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold ILMN.

StrongBuy: 8
Buy: 3
Hold: 6
Sell: 2
StrongSell: 1

What are the forecasts/targets for the ILMN price?

Analysts Target Price	195.8	2.6%

Illumina (ILMN) - Fundamental Data Overview as of 17 August 2026

Market Cap USD = 28.4b (28.4b USD * 1.0 USD.USD)
P/E Trailing = 35.0672
P/E Forward = 35.2113
P/S = 6.3155
P/B = 10.0007
P/EG = 2.6666
Revenue TTM = 4.49b USD
EBIT TTM = 1.09b USD
EBITDA TTM = 1.36b USD
Long Term Debt = 1.49b USD (from longTermDebt, last fiscal year)
Short Term Debt = 582.0m USD (from shortTermDebt, last quarter)
Debt = 3.08b USD (from shortLongTermDebtTotal, last quarter) + Leases 555.0m
Net Debt = 1.91b USD (calculated: Debt 3.08b - CCE 1.17b)
Enterprise Value = 30.3b USD (28.4b + Debt 3.08b - CCE 1.17b)
Interest Coverage Ratio = 10.79 (Ebit TTM 1.09b / Interest Expense TTM 101.0m)
EV/FCF = 32.26x (Enterprise Value 30.3b / FCF TTM 939.0m)
FCF Yield = 3.10% (FCF TTM 939.0m / Enterprise Value 30.3b)
FCF Margin = 20.90% (FCF TTM 939.0m / Revenue TTM 4.49b)
Net Margin = 18.36% (Net Income TTM 825.0m / Revenue TTM 4.49b)
Gross Margin = 66.79% ((Revenue TTM 4.49b - Cost of Revenue TTM 1.49b) / Revenue TTM)
Gross Margin QoQ = 66.44% (prev 66.09%)
Tobins Q-Ratio = 4.56 (Enterprise Value 30.3b / Total Assets 6.65b)
Interest Expense / Debt = 3.28% (Interest Expense 101.0m / Debt 3.08b)
Taxrate = 18.72% (190.0m / 1.01b)
NOPAT = 886.0m (EBIT 1.09b * (1 - 18.72%))
Current Ratio = 1.80 (Total Current Assets 2.83b / Total Current Liabilities 1.58b)
Debt / Equity = 1.09 (Debt 3.08b / totalStockholderEquity, last quarter 2.84b)
Debt / EBITDA = 1.40 (Net Debt 1.91b / EBITDA 1.36b)
Debt / FCF = 2.04 (Net Debt 1.91b / FCF TTM 939.0m)
Total Stockholder Equity = 2.65b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.95% (Net Income 825.0m / Total Assets 6.65b)
RoE = 31.08% (Net Income TTM 825.0m / Total Stockholder Equity 2.65b)
RoCE = 26.30% (EBIT 1.09b / Capital Employed (Equity 2.65b + L.T.Debt 1.49b))
RoIC = 16.32% (NOPAT 886.0m / Invested Capital 5.43b)
WACC = 9.07% (E(28.4b)/V(31.5b) * Re(9.77%) + D(3.08b)/V(31.5b) * Rd(3.28%) * (1-Tc(0.19)))
Discount Rate = 9.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -89.62 | Cagr: -1.70%
[DCF] Terminal Value 71.54% ; FCFF base≈975.8m ; Y1≈906.4m ; Y5≈821.7m
[DCF] Fair Price = 64.15 (EV 11.6b - Net Debt 1.91b = Equity 9.69b / Shares 151.0m; r=9.07% [WACC]; 5y FCF grow -8.92% → 2.50% )
EPS Correlation: 95.50 | EPS CAGR: 125.1% | SUE: 0.32 | # QB: 0
Revenue Correlation: -45.62 | Revenue CAGR: -0.91% | SUE: 1.93 | # QB: 4
EPS current Quarter (2026-09-30): EPS=1.36 | Chg30d=-0.89% | Revisions=-50% | Analysts=16
EPS current Year (2026-12-31): EPS=5.36 | Chg30d=+2.41% | Revisions=+17% | GrowthEPS=+10.7% | GrowthRev=+6.5%
EPS next Year (2027-12-31): EPS=6.08 | Chg30d=+2.57% | Revisions=+12% | GrowthEPS=+13.5% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: -7% (up=5, down=6)